fulvestrant has been researched along with casein kinase ii in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gorodeski, GI; Li, X; Zhou, L | 1 |
| Fichtner, I; Frogne, T; Issinger, OG; Lykkesfeldt, AE; Stenvang, J; Yde, CW | 1 |
2 other study(ies) available for fulvestrant and casein kinase ii
| Article | Year |
|---|---|
Estrogen regulates epithelial cell deformability by modulation of cortical actomyosin through phosphorylation of nonmuscle myosin heavy-chain II-B filaments.
Topics: Actins; Actomyosin; Casein Kinase II; Cells, Cultured; Epithelial Cells; ErbB Receptors; Estradiol; Estrogen Receptor alpha; Estrogens; Extracellular Signal-Regulated MAP Kinases; Fulvestrant; Humans; MAP Kinase Signaling System; Myosin Heavy Chains; Nonmuscle Myosin Type IIB; Phosphorylation | 2006 |
Induction of cell death in antiestrogen resistant human breast cancer cells by the protein kinase CK2 inhibitor DMAT.
Topics: Antineoplastic Agents; Apoptosis; Benzimidazoles; Breast Neoplasms; Casein Kinase II; Caspases; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Polyunsaturated Alkamides; Proto-Oncogene Proteins c-bcl-2; Tamoxifen; Time Factors; Transfection | 2007 |